AMINEX THERAPEUTICS

Aminex Therapeutics, Inc. is a drug development company focused on the discovery, development, and commercialization of suppressor cell modulators (SCM), a new class of small molecule cancer immunotherapies that enable the immune system to attack cancer by regulating myeloid-derived suppressor cells. Aminex has extensively demonstrated, in animal trials, the potential of its lead drug, AMX-513, to be effective alone and to improve overall therapy when used in combination with other cancer treatments. Aminex's vision is to make significant treatment contributions for a wide range of cancers and to ease the rising costs of cancer therapy.